| scholarly article | Q13442814 |
| P50 | author | Marcel Spaargaren | Q37383338 |
| Richard W Groen | Q57549123 | ||
| P2093 | author name string | Helen P Meijer | |
| Melanie D Klok | |||
| Patrick W B Derksen | |||
| Steven T Pals | |||
| Susanne van Eeden | |||
| Esther P M Tjin | |||
| Irma Vogelzang | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 760-768 | |
| P577 | publication date | 2005-09-27 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma | |
| P478 | volume | 107 |
| Q33424270 | A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors |
| Q40020532 | Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases. |
| Q41592550 | Alteration of angiogenesis in Helicobacter heilmannii-induced mucosa-associated lymphoid tissue lymphoma: interaction with c-Met and hepatocyte growth factor |
| Q35082524 | An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease |
| Q53221535 | Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. |
| Q39449489 | Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer |
| Q38952158 | Dendritic cell-mediated survival signals in Eμ-Myc B-cell lymphoma depend on the transcription factor C/EBPβ. |
| Q34198905 | Development of c-MET pathway inhibitors |
| Q33896731 | Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas |
| Q37137157 | Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma |
| Q35956303 | Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma |
| Q57791826 | Extracellular Matrix Influencing HGF/c-MET Signaling Pathway: Impact on Cancer Progression |
| Q24304887 | FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells |
| Q48601823 | HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma |
| Q39675475 | HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. |
| Q28509645 | Hepatocyte Growth Factor Modulates Interleukin-6 Production in Bone Marrow Derived Macrophages: Implications for Inflammatory Mediated Diseases |
| Q61795626 | Hepatocyte Growth Factor: A Microenvironmental Resource for Leukemic Cell Growth |
| Q37733681 | Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo |
| Q42747876 | Hepatocyte growth factor and the hepatocyte growth factor receptor signalling complex as targets in cancer therapies |
| Q36646078 | High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma |
| Q52593925 | How Biophysical Forces Regulate Human B Cell Lymphomas. |
| Q37218234 | Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas |
| Q36526999 | Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. |
| Q53173084 | Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. |
| Q38868904 | Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma |
| Q58164582 | MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients |
| Q34033952 | MET receptor sequence variants R970C and T992I lack transforming capacity |
| Q60909538 | MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk |
| Q38008247 | MET: a promising anticancer therapeutic target |
| Q38255480 | Mechanisms of hepatocyte growth factor activation in cancer tissues |
| Q42098747 | Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses |
| Q52560170 | Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma. |
| Q36208267 | Stromal cell contribution to human follicular lymphoma pathogenesis. |
| Q37427337 | Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines |
| Q33943962 | Targeting MET transcription as a therapeutic strategy in multiple myeloma |
| Q89966992 | The Emerging Role of the c-MET-HGF Axis in Non-small Lung Cancer Tumor Immunology and Immunotherapy |
| Q41909242 | The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas |
| Q28069836 | The role of HGF/c-MET signaling pathway in lymphoma |
| Q38727975 | The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells |
| Q35872516 | c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death |
| Q39888526 | c-Met signaling promotes IL-6-induced myeloma cell proliferation |
Search more.